Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661999 · ClinicalTrials.gov registry record · Phase 3
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
A Phase 3 study of Lymphoma and Leukemia, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 502
- Enrollment target
- 2
- Study locations
NCT00661999 is a Phase 3 study of Lymphoma and Leukemia that has completed, run by Mayo Clinic. The registered enrollment target is 502 participants, roughly in line with the 482-participant average among 299 other Lymphoma trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT00661999, a Phase 3 study of Lymphoma and Leukemia, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 502 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether giving darbepoetin alfa (DA) together with intravenous iron or oral iron is more effective than giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy. PURPOSE: This randomized phase III trial is studying giving darbepoetin alfa together with iron to see how well it works compared with giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy in patients with cancer.
Conditions Studied
Interventions
- OTHER placebo
- BIOLOGICAL darbepoetin alfa
- DIETARY_SUPPLEMENT ferrous sulfate
- DRUG sodium ferric gluconate complex in sucrose
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661999
The ClinicalTrials.gov registry entry for NCT00661999 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 502 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 482-participant average among 299 other Lymphoma trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT00661999 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00661999 about?
NCT00661999 is a clinical study titled "Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer". RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether giving darbepoetin alfa (DA) together with intravenous iron or oral iron is more effective than giving darbepoetin alfa...
What is the current status of trial NCT00661999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 502 participants. The study started on 2006-01. Estimated completion is 2009-03.
What conditions does trial NCT00661999 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Anemia, Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00661999?
The interventions under investigation include: placebo (OTHER), darbepoetin alfa (BIOLOGICAL), ferrous sulfate (DIETARY_SUPPLEMENT), sodium ferric gluconate complex in sucrose (DRUG).
Who is sponsoring clinical trial NCT00661999?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00661999 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.